Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey

Abstract

BACKGROUND: Between March and December, 2020, more than 20 000 laboratory-confirmed cases of SARS-CoV-2 infection were reported in Zambia. However, the number of SARS-CoV-2 infections is likely to be higher than the confirmed case counts because many infected people have mild or no symptoms, and limitations exist with regard to testing capacity and surveillance systems in Zambia. We aimed to estimate SARS-CoV-2 prevalence in six districts of Zambia in July, 2020, using a population-based household survey. METHODS: Between July 4 and July 27, 2020, we did a cross-sectional cluster-sample survey of households in six districts of Zambia. Within each district, 16 standardised enumeration areas were randomly selected as primary sampling units using probability proportional to size. 20 households from each standardised enumeration area were selected using simple random sampling. All members of selected households were eligible to participate. Consenting participants completed a questionnaire and were tested for SARS-CoV-2 infection using real-time PCR (rtPCR) and anti-SARS-CoV-2 antibodies using ELISA. Prevalence estimates, adjusted for the survey design, were calculated for each diagnostic test separately, and combined. We applied the prevalence estimates to census population projections for each district to derive the estimated number of SARS-CoV-2 infections. FINDINGS: Overall, 4258 people from 1866 households participated in the study. The median age of participants was 18·2 years (IQR 7·7-31·4) and 50·6% of participants were female. SARS-CoV-2 prevalence for the combined measure was 10·6% (95% CI 7·3-13·9). The rtPCR-positive prevalence was 7·6% (4·7-10·6) and ELISA-positive prevalence was 2·1% (1·1-3·1). An estimated 454 708 SARS-CoV-2 infections (95% CI 312 705-596 713) occurred in the six districts between March and July, 2020, compared with 4917 laboratory-confirmed cases reported in official statistics from the Zambia National Public Health Institute. INTERPRETATION: The estimated number of SARS-CoV-2 infections was much higher than the number of reported cases in six districts in Zambia. The high rtPCR-positive SARS-CoV-2 prevalence was consistent with observed community transmission during the study period. The low ELISA-positive SARS-CoV-2 prevalence might be associated with mitigation measures instituted after initial cases were reported in March, 2020. Zambia should monitor patterns of SARS-CoV-2 prevalence and promote measures that can reduce transmission. FUNDING: US Centers for Disease Control and Prevention.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 34

1. 1.

   Chipimo PJ, Barradas DT, Kayeyi N, First 100 persons with COVID-19—Zambia, March 18–April 28, 2020. MMWR Morb Mortal Wkly Rep2020; 69: 1547–48.

   Not in our library10.15585/mmwr.mm6942a5

2. 2.

   Zambia Ministry of Health. Press briefing on COVID-19 and additional preventive and control measures. 3 17, 2020. https://www.moh.gov.zm/?wpfb_dl=145 (accessedFeb 8, 2021).

   Not in our library

3. 3.
   Evidence Supporting Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic · 2020

   No notice
4. 4.
   Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020 · 2020

   No notice
5. 5.

   Struyf T, Deeks JJ, Dinnes J, Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst Rev2020; 7: CD013665.

   Not in our library10.1002/14651858.cd013665

6. 6.

   Nkengasong J Let Africa into the market for COVID-19 diagnostics. Nature2020; 580: 565.

   Not in our library10.1038/d41586-020-01265-0

7. 7.

   Anand S, Montez-Rath M, Han J, Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study. Lancet2020; 396: 1335–44.

   Not in our library10.1016/s0140-6736(20)32009-2

8. 8.
   Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020 · 2021

   No notice
9. 9.

   Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet2020; 396: 535–44.

   Not in our library10.1016/s0140-6736(20)31483-5

10. 10.
    SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys · 2020

    No notice
11. 11.

    Mozambique National Institute of Health. Bicycle taxi operators with greater exposure to Coronavirus in Quelimane. 9 3, 2020. https://covid19.ins.gov.mz/operadores-de-taxi-bicicleta-com-maior-exposicao-ao-coronavirus-em-quelimane/ (accessedFeb 8, 2021; in Portuguese).

    Not in our library

12. 12.

    Mozambique National Institute of Health. Most people exposed to COVID-19 have no symptoms 2020. 8 31, 2020. https://covid19.ins.gov.mz/maior-parte-das-pessoas-expostas-a-covid-19-nao-apresenta-sintomas/ (accessedFeb 8, 2021; in Portuguese).

    Not in our library

13. 13.

    Alemu BN, Addissie A, Mamo G, Sero-prevalence of anti-SARS-CoV-2 antibodies in Addis Ababa, Ethiopia. bioRxiv2020; published online Oct 13. (preprint).

    Not in our library10.1101/2020.10.13.337287

14. 14.

    Majiya H, Aliyu-Paiko M, Balogu VT, Seroprevalence of COVID-19 in Niger State. medRxiv2020; published online Aug 5. (preprint).

    Not in our library10.1101/2020.08.04.20168112

15. 15.

    National Institute for Communicable Diseases. SARS-CoV-2 seroprevalence in the Cape Town Metropolitan Subdistricts after the peak of infections. https://www.nicd.ac.za/wp-content/uploads/2020/09/COVID-19-Special-Public-Health-Surveillance-Bulletin_Issue-5.pdf (accessedFeb 22, 2021).

    Not in our library

16. 16.

    Shaw J, Meiring M, Cummins T, Higher SARS-CoV-2 seroprevalence in workers with lower socioeconomic status in Cape Town, South Africa. Research Square2020; published online Dec 29. (preprint).

    Not in our library10.21203/rs.3.rs-136543/v1

17. 17.

    Chibwana M, Jere K, Kamng’ona R, High SARS-CoV-2 seroprevalence in health care workers but relatively low numbers of deaths in urban Malawi. medRxiv2020; published online Aug 5. (preprint).

    Not in our library10.1101/2020.07.30.20164970v3

18. 18.
    Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors · 2021

    No notice
19. 19.

    Ojal J, Brand S, Were V, Revealing the extent of the COVID-19 pandemic in Kenya based on serological and PCR-test data. medRxiv2020; published online Sept 3. (preprint).

    Not in our library10.1101/2020.09.02.20186817v1

20. 20.

    Zambia Central Statistical Office. 2010 census of population and housing. Population and demographic projections 2011–2035. 7, 2013. https://www.zamstats.gov.zm/phocadownload/Zambia%20Census%20Projection%202011%20-%202035.pdf (accessedFeb 8, 2021).

    Not in our library

21. 21.

    WHO. Coronavirus disease (COVID-19) technical guidance: the Unity Studies: early investigation protocols. 2020. Geneva: World Health Organization. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/early-investigations (accessedFeb 8, 2021).

    Not in our library

22. 22.

    Centers for Disease Control and Prevention. CDC 2019-novel coronavirus (2019-nCoV) real-time RT-PCR diagnostic panel. 7 13, 2020. https://www.fda.gov/media/134922/download (accessedFeb 22, 2020).

    Not in our library

23. 23.

    Pullano G, Di Domenico L, Sabbatini CE, Underdetection of cases of COVID-19 in France threatens epidemic control. Nature2021; 590: 134–39.

    Not in our library10.1038/s41586-020-03095-6

24. 24.

    Mwenda M, Saasa N, Sinyange N, Detection of B.1.351 SARS-CoV-2 variant strain—Zambia, December 2020. MMWR Morb Mortal Wkly Rep2021; published online Feb 17..

    Not in our library10.15585/mmwr.mm7008e2

25. 25.
    Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa · 2020

    No notice
26. 26.

    Vizcarra P, Pérez-Elías MJ, Quereda C, Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. Lancet HIV2020; 7: e554–64.

    Not in our library10.1016/s2352-3018(20)30164-8

27. 27.

    Byrd KM, Beckwith CG, Garland JM, SARS-CoV-2 and HIV coinfection: clinical experience from Rhode Island, United States. J Int AIDS Soc2020; 23: e25573.

    Not in our library10.1002/jia2.25573

28. 28.

    Karmen-Tuohy S, Carlucci PM, Zervou FN, Outcomes among HIV-positive patients hospitalized with COVID-19. J Acquir Immune Defic Syndr2020; 85: 6–10.

    Not in our library10.1097/qai.0000000000002423

29. 29.

    Inciarte A, Gonzalez-Cordon A, Rojas J, Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study. AIDS2020; 34: 1775–80.

    Not in our library10.1097/qad.0000000000002643

30. 30.

    Byambasuren O, Cardona M, Bell K, Clark J, McLaws M-L, Glasziou P. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. Off J Assoc Med Microbiol Infect Dis Canada2020; 5: 223–34.

    Not in our library10.3138/jammi-2020-0030

31. 31.

    Davies NG, Klepac P, Liu Y, Prem K, Jit M, Eggo RM. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med2020; 26: 1205–11.

    Not in our library10.1038/s41591-020-0962-9

32. 32.

    US Food and Drug Administration. Serology test evaluation report for “SARS-COV-2 ELISA (IgG)” from Euroimmun. 6 21, 2020. https://www.accessdata.fda.gov/cdrh_docs/presentations/maf/maf3246-a001.pdf (accessedFeb 8, 2021).

    Not in our library

33. 33.

    Tso FY, Lidenge SJ, Peña PB, High prevalence of pre-existing serological cross-reactivity against SARS-CoV-2 in sub-Sahara Africa. Int J Infect Dis2020; 102: 557–83.

    Not in our library10.1016/j.ijid.2020.10.104

34. 34.

    WHO. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays: interim guideance, 11 September 2020. Geneva: World Health Organization. https://apps.who.int/iris/handle/10665/334253 (accessedFeb 8, 2021).

    Not in our library

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.